seed
Stage
2016
Founded
2
Investors
About
aptaTargets is a clinical-stage biotech company developing innovative therapies for acute neurological diseases. Their lead compound, ApTOLL, is an RNA aptamer targeting Toll-like receptor 4, currently in Phase IIb clinical trials for acute ischemic stroke.
Explore aptaTargets's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.